Abstract

BackgroundOcriplasmin (Jetrea) is using for the treatment of symptomatic vitreomacular adhesion. This enzyme undergoes rapid inactivation and limited activity duration as a result of its autolytic nature after injection within the eye. Moreover, the proteolytic activity can cause photoreceptor damage, which may result in visual impairment in more serious cases.ResultsThe present research aimed to reduce the disadvantages of ocriplasmin using site-directed mutagenesis. To reduce the autolytic activity of ocriplasmin in the first variant, lysine 156 changed to glutamic acid and, in the second variant for the proteolytic activity reduction, alanine 59 mutated to threonine. The third variant contained both mutations. Expression of wild type and three mutant variants of ocriplasmin constructs were done in the Pichia pastoris expression system. The mutant variants were analyzed in silico and in vitro and compared to the wild type. The kinetic parameters of ocriplasmin variants showed both variants with K156E substitution were more resistant to autolytic degradation than wild-type. These variants also exhibited reduced Kcat and Vmax values. An increase in their Km values, leading to a decreased catalytic efficiency (the Kcat/Km ratio) of autolytic and mixed variants. Moreover, in the variant with A59T mutation, Kcat and Vmax values have reduced compared to wild type. The mix variants showed the most increase in Km value (almost 2-fold) as well as reduced enzymatic affinity to the substrate. Thus, the results indicated that combined mutations at the ocriplasmin sequence were more effective compared with single mutations.ConclusionsThe results indicated such variants represent valuable tools for the investigation of therapeutic strategies aiming at the non-surgical resolution of vitreomacular adhesion.

Highlights

  • Ocriplasmin (Jetrea) is using for the treatment of symptomatic vitreomacular adhesion

  • In Silico Analysis of Ocriplasmin Variants Structural analyses performed using the protein interaction calculator (PIC) web server revealed that the substitution of alanine 59 for threonine (A59T) significantly reduces proteolytic activities and the substitution of lysine156 for glutamic acid (K156E) notably affects the autolytic function of the enzyme

  • The molecular docking simulations of the substrate S-2403 with different variants of ocriplasmin showed that the minimum free binding energy (ΔG) between them in the high number conformations cluster were respectively − 7.67, − 6.93, − 6.75, − 5.84 kcal/mol for substrate-wild type ocriplasmin, substrate-autolytic type ocriplasmin, substrateproteolytic type ocriplasmin, and substrate-mixed type ocriplasmin

Read more

Summary

Introduction

Ocriplasmin (Jetrea) is using for the treatment of symptomatic vitreomacular adhesion. This enzyme undergoes rapid inactivation and limited activity duration as a result of its autolytic nature after injection within the eye. Symptomatic vitreomacular adhesion or vitreomacular traction may cause edema, macular distortion and, form macular holes. This sight-threatening condition relates to decreased visual acuity, photopsia and, metamorphopsia [1,2,3,4]. Two pivotal Phase III trials, including ocriplasmin for Intravitreous Injection-Traction Release without Surgical Treatment [MIVI-TRUST], confirmed the efficacy and safety of ocriplasmin in treating symptomatic vitreomacular adhesion. The Food and Drug Administration approved ocriplasmin in 2012 for treating vitreomacular traction [4, 9]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call